Table 1.
Patient Characteristics
| N=32 | |
|---|---|
| Age, median (range) | 59 (23–80) |
| Gender, n (%) | |
| Female | 12 (38) |
| Male | 20 (63) |
| Disease, n (%) | |
| Diffuse large B-cell lymphoma or high grade B-lymphoma | 30 (94) |
| Transformed follicular lymphoma | 2 (6) |
| Status, n (%) | |
| Infused inpatient | 25 (78) |
| Infused outpatient | 7 (22) |
| CAR-T therapy, n (%) | |
| Tisagenlecleucel (tisa-cel) | 4 (13) |
| Axicabtagene ciloleucel (axi-cel) | 28 (88) |
| Length of hospital stay, median (range) | 13 (4–36) |
| Overall response to CAR-T (at 3 months), n (%) | |
| Complete remission | 9 (28) |
| Partial remission | 6 (19) |
| Progressive disease | 15 (47) |
| Early death after infusion | 2 (6) |
| Worst cytokine release syndrome (CRS) grade, n (%) | |
| 0 | 3 (9) |
| 1 | 13 (41) |
| 2 | 12 (38) |
| 3 | 2 (6) |
| 4 | 2 (6) |
| Neurotoxicity, n (%) | |
| No | 9 (28) |
| Yes | 23 (72) |
| Worst neurotoxicity grade, n (%) | |
| 0 | 9 (28) |
| 1 | 3 (9) |
| 2 | 9 (28) |
| 3 | 9 (28) |
| 4 | 2 (6) |
| Doses of tocilizumab received, n (%) | |
| 0 | 17 (53) |
| 1 | 3 (9) |
| 2 | 5 (16) |
| 3 | 3 (9) |
| 4 | 4 (13) |
| Received filgrastim, n (%) | |
| No | 12 (38) |
| Yes | 20 (63) |
| Required transfusion inpatient, n (%) | |
| No | 19 (59) |
| Yes | 13 (41) |
| Require transfusion outpatient, n (%) | |
| No | 19 (63) |
| Yes | 11 (37) |
| Confirmed infectious complication, n (%) | |
| No | 11 (34) |
| Yes | 21 (66) |